How EVEA™ works
Four steps. Two clinic visits. No lab culture days.
The entire culture phase happens in-vivo inside the EVEA™ device — removing the need for an embryology cleanroom and incubator bank.
EVEA™ occupies the clinical and economic space between intrauterine insemination and full conventional IVF — a lower-infrastructure path to embryo culture for indicated, good-prognosis patients. It does not replace IVF; cases it cannot serve escalate to IVF, expanding the funnel rather than competing with it.
Widely available, low success per cycle — many patients escalate.
Higher success than IUI. Uses existing operating theatre, andrology lab and embryology staff. Eliminates the cleanroom, incubator bank and HEPA build that full IVF requires.
Major-city centres, full embryology lab — the backstop for complex cases.
The entire culture phase happens in-vivo inside the EVEA™ device — removing the need for an embryology cleanroom and incubator bank.
Conventional IVF cultures embryos in open dishes for 3–5 days, requiring a HEPA-filtered cleanroom, a bank of CO₂ culture incubators and continuous air-quality monitoring. EVEA™ moves that phase in-vivo — removing the single most infrastructure-heavy constraint in ART. IVC still uses an operating theatre, an andrology lab and microscopes; it removes the cleanroom, not all lab equipment.
No HEPA-filtered lab build, no continuous air monitoring, no dedicated embryology space — the single largest barrier to deploying ART outside major cities.
No bank of CO₂ culture incubators for open culture. The multi-day open-culture environment disappears entirely.
Substantially fewer embryologist-hours per cycle than a conventional ART centre — easing the specialist-staffing constraint.
Single-use, manufactured to ISO 13485, supplied per cycle.
Standardised loading, retention and assessment protocols, with structured clinical training delivered before first cycle.
QMS scaffolding deployed with every activation, jurisdiction-aware.
Malaysia regulatory approval route defined; Hong Kong patent filed with positive CNIPA search report; comprehensive freedom-to-operate assessment completed.
Request a deployment briefing for medical directors, regulators and clinical teams.
Request a briefing →